Overexpression of ABL1 (ABL Proto-Oncogene 1) gene is associated with shorter survival in LUAD patients, and animal studies suggest that its inhibitors are effective in treating metastatic NSCLC [53]. The gene discussed is ABL1; the disease is non-small cell lung carcinoma.